TasP is not enough Stipulated that TasP is effective in reducing infectiousness of the treated person – But much more is required. TasP requires effective.

Slides:



Advertisements
Similar presentations
The Connection Between STDs and HIV
Advertisements

No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
Women and ARV-based Prevention: Challenges and Opportunities Tim Mastro, MD, DTM&H AIDS 2014 Melbourne, Australia 24 July 2014.
HIV treatment as prevention Stephen Kegg. 2 Learning Outcomes Overview of HIV management HIV transmission risks Current prevention strategies Which new.
Impact of Age and Race on New HIV Infections among Men who have Sex with Men in Los Angeles County Shoshanna Nakelsky, MPH Division of HIV and.
Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.
PEPFAR Emmanuel Njeuhmeli, MD, MPH, MBA Senior Biomedical Prevention Advisor and Co-Chair PEPFAR Male Circumcision Technical Working Group Office of HIV/AIDS.
Modelling HIV/AIDS in Southern Africa Centre for Actuarial Research (CARe) A Research Unit of the University of Cape Town.
HIV in the United Kingdom: Setting the scene
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
1 MMWR (60), Of all with HIV infection, ~850,000 individuals do not have suppressed HIV RNA (72%) 100 % 75% 50% 25% 80 % 77 % 66 % 77 % 89 % Gaps.
Treatment as prevention (TASP) for HIV and HCV: The evidence and modelling Peter Vickerman.
Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
User Perspective on ARV-Based HIV Prevention Suwat Chariyalertsak, MD., Dr.PH Research Institute for Health Sciences Chiang Mai University.
How well are we doing in preventing HIV and how can we do better?
HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
Use of Antivirals in Prevention: Current Challenges and Controversies: Treatment for Prevention IAS 2011 Nancy Padian Senior technical consultant OGAC/PEPFAR.
Can we reach UNAIDS targets and will this lead to the elimination of HIV in the UK? Dr Valerie Delpech Head of national HIV surveillance.
What does PrEP mean for people living with HIV? Edwin J Bernard Co-ordinator, HIV Justice Network Consultant, GNP+
Monitoring the effects of ARV treatment programmes on prevention Gabriel Mwaluko 1, Mark Urassa,2, John Changalucha,2, Ties Boerma 3 1 TANESA Project,
Voluntary Counseling and Testing (VCT) for HIV
Prevention with Positives; Using Multiple Strategies to Involve Persons Living with HIV in Prevention. TASO Uganda. Emmanuel Odeke,
LIMPOPO PROVINCIAL MEN’S SECTORS/BROTHERS FOR LIFE PRESENTED BY: RAPAKWANA JOHANNAH MANAGER:GAAP in HIV & AIDS & STIs Directorate DEPT OF HEALTH AND SOCIAL.
What do models estimate to be the impacts on HIV incidence of various percentages of people with HIV on ART ? National AIDS Trust Treatment as Prevention.
AIDS supplement. History of HIV Originated in Africa in the late 1950’s Originally found in nonhuman primates and may have mutated First documented in.
Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.
ART for Prevention From Evidence to Action Wafaa El-Sadr, MD, MPH ICAP-Columbia University.
Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina.
JORDAN E. LAKE, MD, MSC AAHU SEPTEMBER 2014 Prevention for Positives.
1 st International Treatment as Prevention (TasP) Workshop Overview British Columbia Centre for Excellence in HIV/AIDS Julio Montaner MD, DSc(hon), FRCPC,
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)
HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4
A divergent tale of two cities Why HIV control in men who have sex with men may have differed between London and San Francisco since 2006? Colin Brown.
Exploring the potential impact of ART in reducing HIV transmission. Geoff Garnett, Jeff Eaton, Tim Hallett & Ide Cremin Imperial College London.
STATE OF THE STATE SHELLEY LUCAS HIV/STD PREVENTION & CARE BRANCH DEPT OF STATE HEALTH SERVICES AUGUST 3, 2015.
Introduction to NCHHSTP National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Office of the Director Jonathan Mermin, MD, MPH National.
Providing Treatment, Restoring Hope Secondary Prevention as part of HIV Clinical Care Martine Etienne, MPH, DrPH University of Maryland School of Medicine.
Understanding temporal trends in HIV prevalence, incidence and ARV Dr Valerie Delpech Head of HIV surveillance Public Health England.
Hepatitis C: The Silent Epidemic Wednesday, October 21, 2015 John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.
High-impact interventions. Number of people living with HIV who were not receiving antiretroviral therapy, 2014 and 2015 Source: UNAIDS estimates, 2014.
JORDAN E. LAKE, MD, MSC AAHU AUGUST 2015 Prevention for Positives.
Getting to Zero: Will San Francisco be the first city to succeed? Diane Havlir, MD, Professor of Medicine, UCSF, Chief HIV San Francisco General Hospital.
ARV-Based Prevention: Perspective from Epidemiology & Modelling Tim Hallett Imperial College London.
PrEP Update: The science, new tools, and next steps Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC “The findings and conclusions in this.
Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.
Antiretrovirals for HIV Prevention: Progress and Challenges Kenneth H. Mayer, M.D. Brown/Miriam/Fenway.
HIV in America What’s New in 2012 Christopher Hurt, MD Clinical Assistant Professor NC AIDS Education and Training Center 2012 HIV Update.
HIV in India David S. Hausner American Embassy School 8 th Grade Population Project 24 February 2012.
HIV Prevention: A Winnable Battle Centers for Disease Control and Prevention.
More Than Just a Cut: Voluntary Medical Male Circumcision Programs Can Address Low HIV Testing and Counseling Usage and ART Enrollment among Young Men:
HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.
N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER HIV Prevention in Clinical Care Settings Jeanne Marrazzo, MD, MPH Professor, Division of Allergy and Infectious.
Pre-exposure Prophylaxis (PrEP) for HIV Prevention: What’s the Future? Joanne Stekler, MD MPH Assistant Professor of Medicine University of Washington.
HIV/AIDS in Utah Edwin Espinel HIV Counseling & Testing, Partner Services Program Coordinator University of Utah May 2013 Utah Department of Health Bureau.
Treatment as prevention: policy and programmatic considerations
Information about HIV Prevention Options
IAS Satellite Session 25th July 2017 Daniel Were, PhD
Entry into care Failure to initiate timely HIV care after diagnosis is common ~75% of newly diagnosed link to care within 6-12 months Delayed entry into.
HIV and the ART of Prevention
AIDSACTIONBALTIMORE PREP UP TOWN HALL
100 Partners PrEP[5] Efficacy 75% Adherence 81% 80
HIV.
Lesson 3: Treatment as Prevention
Overview of HIV Prevention Cascade Discussions. Geoff Garnett
Presentation transcript:

TasP is not enough Stipulated that TasP is effective in reducing infectiousness of the treated person – But much more is required. TasP requires effective behavioral interventions – Testing, access, linkage, retention, adherence – Processes that occur outside of the clinic Prevention requires a diverse portfolio of services so that there is something attractive for everyone. – Many prevention services are more cost effective than TasP Social benefits are Important

CDC Cascade MMWR December 2, 2011 / 60(47);

SF DPH, Annual Report, 2011

Nicole Johns on 20 November 2012, Philadelphia EMA Ryan White Part A Planning Council and HIV Prevention Group.

Nicole Johns on 20 November 2012, the Philadelphia EMA Ryan White Part A Planning Council and the Philadelphia HIV Prevention Group.

Figure 2. Estimated trends in HIV incidence and sexual behaviour. Phillips AN, Cambiano V, Nakagawa F, Brown AE, et al. (2013) Increased HIV Incidence in Men Who Have Sex with Men Despite High Levels of ART-Induced Viral Suppression: Analysis of an Extensively Documented Epidemic. PLoS ONE 8(2): e doi: /journal.pone

Why is TasP not working? Requires engagement, testing, linkage, adherence. – Processes occur outside of clinics and clinical thinking. – Only 28% with HIV in the US are effectively treated. – Only 44% in San Francisco (a privileged setting). Risk compensation In couples, a third of infections arise from outside the primary partnership. 10 to 50% of new infections come from acute infections, before they can be diagnosed and treated.

The Prevention Portfolio is Diverse: HIV Testing and counseling Condoms Circumcision Needle Exchange Interactive client based counseling – For adherence, for harm reduction Treatment for Positives PREP for Negatives Listen to what people want

Nothing passes through condoms: Use with confidence

Learning From Prior Success Condom Use in Early 1980s “Love Carefully” Uganda 1990s Seroadaptive Behaviors Late 1990s Common Characteristics – Grass Roots Initiatives – Focus on immediate concerns – Motivated by Sexual and Social Goals

Risk Reduction During PREP Use By Drug Concentration Drug Concentration Comensurate with Doses HIV Risk Reduction* 95% Confidence Interval 2 per week76%56% to 96% 4 per week96%90% to >99% 7 per week99%96% to >99% Anderson et al, Science Translational Medicine :151ra125 *Compared with placebo, after controlling for numbers of partners, condom use, STIs, age, site

Adequate Adherence to PREP is Feasible Drug Detection* Region (%) 94%43% USANon USA Time Points Median TFV-DP Level 2619 P < *Detection of TFV/FTC/TFV-DP or FTC-TP in plasma or PBMC

Figure 2. Comparison of PrEP versus earlier ART initiation for keeping couples “ alive and HIV free at 50. ” Hallett TB, Baeten JM, Heffron R, Barnabas R, et al. (2011) Optimal Uses of Antiretrovirals for Prevention in HIV-1 Serodiscordant Heterosexual Couples in South Africa: A Modelling Study. PLoS Med 8(11): e doi: /journal.pmed

Ways PrEP Could Enable Treatment Decreased burden on HIV treatment programs, Motivates HIV testing, – Provides benefits to people hoping they are uninfected, – Seropositives may be linked into care. More timely identification of acute infections, – Allows earlier therapy initiation, – Enables cure research for acute infection. Greater familiarity with antiretroviral therapy, – A diversity of providers serving a diversity of people, – Uninfected people become aware of therapy and HIV. May destigmatize therapy and the people who use it.

Social Benefits 18 TasPOther Prevention Less HIV Transmission Decreased (non- pulmonary) TB Disease Prevention other STI transmission Social empowerment of women, youth, LGBT communities, communities of color; housing, jobs, food; family planning.

Combination Prevention

A Combination of Approaches is Essential for Increasing Uptake and Use of Prevention Methods to Levels Required to End AIDS 20